Literature DB >> 24293099

Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.

Adelheid Wiemer-Kruel1, H Woerle2, K Strobl1, T Bast1.   

Abstract

We are reporting on a 13.5-year-old girl with tuberous sclerosis complex (TSC) who was treated with everolimus because of giant cell astrocytoma and bilateral angiomyolipoma. She suffered from pharmacoresistant partial epilepsy with clusters of tonic and tonic-clonic seizures. Treatment with carbamazepine and sulthiame had led to a stable situation for more than 2.5 years. The dosage of everolimus had to be increased and refractory status epilepticus followed after 12 days. In the absence of any other possible cause, we believe that the status epilepticus was provoked by everolimus. So far, only a few cases of possible seizure aggravation by everolimus have been reported. The clinical relevance of possible negative effects in epileptic patients remains unclear. Similar observations should be documented and reported. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293099     DOI: 10.1055/s-0033-1360481

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  5 in total

Review 1.  The mTOR signalling cascade: paving new roads to cure neurological disease.

Authors:  Peter B Crino
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 2.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

3.  Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement.

Authors:  Lawrence S Hsieh; John H Wen; Kumiko Claycomb; Yuegao Huang; Felicia A Harrsch; Janice R Naegele; Fahmeed Hyder; Gordon F Buchanan; Angelique Bordey
Journal:  Nat Commun       Date:  2016-06-01       Impact factor: 14.919

4.  Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.

Authors:  Sharon Samueli; Klaus Abraham; Anastasia Dressler; Gudrun Gröppel; Angelika Mühlebner-Fahrngruber; Theresa Scholl; Gregor Kasprian; Franco Laccone; Martha Feucht
Journal:  Orphanet J Rare Dis       Date:  2016-11-03       Impact factor: 4.123

5.  Clinical patterns and outcomes of status epilepticus in patients with tuberous sclerosis complex.

Authors:  Hatem S Shehata; Hadeer Mahmoud AbdelGhaffar; Mohammed Nasreldin; Alaa Elmazny; Ahmed Abdelalim; Asmaa Sabbah; Nevin M Shalaby
Journal:  Ther Clin Risk Manag       Date:  2017-06-30       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.